# Hemab Therapeutics Holdings, Inc.: financial statements, quarterly

COAG · Nasdaq · CIK 2114044 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/coag.md) · [Financials](/companies/coag/financials.md) · [Filings](/companies/coag/filings.md) · [Insiders](/companies/coag/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/coag/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Research and development | $m | [14.1](/filings/0001193125-26-234386.md) | [12.9](/filings/0001193125-26-344533.md) | [19.5](/filings/0001193125-26-234386.md) | [20.3](/filings/0001193125-26-344533.md) |
| Selling, general and administrative | $m | [2.5](/filings/0001193125-26-234386.md) | [3.2](/filings/0001193125-26-344533.md) | [4.2](/filings/0001193125-26-234386.md) | [5.7](/filings/0001193125-26-344533.md) |
| Operating income | $m | [(16.6)](/filings/0001193125-26-234386.md) | [(16.1)](/filings/0001193125-26-344533.md) | [(23.6)](/filings/0001193125-26-234386.md) | [(26.1)](/filings/0001193125-26-344533.md) |
| Income tax | $m | [(0.2)](/filings/0001193125-26-234386.md) | [0.0](/filings/0001193125-26-344533.md) | [0.0](/filings/0001193125-26-234386.md) | [0.1](/filings/0001193125-26-344533.md) |
| Net income | $m | [(15.3)](/filings/0001193125-26-344533.md) | [(12.2)](/filings/0001193125-26-344533.md) | [(22.7)](/filings/0001193125-26-344533.md) | [(24.2)](/filings/0001193125-26-344533.md) |
| Diluted EPS | $ per share | [(16.18)](/filings/0001193125-26-234386.md) | [(12.91)](/filings/0001193125-26-344533.md) | [(23.98)](/filings/0001193125-26-234386.md) | [(0.80)](/filings/0001193125-26-344533.md) |
| Basic EPS | $ per share | [(16.18)](/filings/0001193125-26-234386.md) | [(12.91)](/filings/0001193125-26-344533.md) | [(23.98)](/filings/0001193125-26-234386.md) | [(0.80)](/filings/0001193125-26-344533.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | [88.0](/filings/0001193125-26-344533.md) | [49.9](/filings/0001193125-26-234386.md) | [237](/filings/0001193125-26-344533.md) |
| Current assets | $m | not reported | not reported | not reported | [193](/filings/0001193125-26-344533.md) | [169](/filings/0001193125-26-234386.md) | [464](/filings/0001193125-26-344533.md) |
| Total assets | $m | not reported | not reported | not reported | [195](/filings/0001193125-26-344533.md) | [175](/filings/0001193125-26-234386.md) | [468](/filings/0001193125-26-344533.md) |
| Current liabilities | $m | not reported | not reported | not reported | [10.7](/filings/0001193125-26-344533.md) | [13.2](/filings/0001193125-26-234386.md) | [12.9](/filings/0001193125-26-344533.md) |
| Total liabilities | $m | not reported | not reported | not reported | [11.3](/filings/0001193125-26-344533.md) | [13.7](/filings/0001193125-26-234386.md) | [13.5](/filings/0001193125-26-344533.md) |
| Shareholders' equity | $m | [(115)](/filings/0001193125-26-344533.md) | [(129)](/filings/0001193125-26-344533.md) | [(141)](/filings/0001193125-26-344533.md) | [(177)](/filings/0001193125-26-344533.md) | [(199)](/filings/0001193125-26-234386.md) | [454](/filings/0001193125-26-344533.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest, us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(13.0)](/filings/0001193125-26-234386.md) | [(15.3) d](/filings/0001193125-26-344533.md) | [(21.6)](/filings/0001193125-26-234386.md) | [(22.6) d](/filings/0001193125-26-344533.md) |
| Capital expenditure | $m | [0.0](/filings/0001193125-26-234386.md) | [0.0 d](/filings/0001193125-26-344533.md) | [0.1](/filings/0001193125-26-234386.md) | [0.0 d](/filings/0001193125-26-344533.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.9](/filings/0001193125-26-234386.md) | [0.9](/filings/0001193125-26-344533.md) | [0.9](/filings/0001193125-26-234386.md) | [30.1](/filings/0001193125-26-344533.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 46,712,117 at 2026-07-31, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-344533.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.